Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZGGS15 in advanced solid tumors
NCT05864573Phase 1Completed
- Sponsor
- Zelgen
- Start
- Jul 2023
- Primary completion
- Jun 2025
- Modality
- IgG Antibodies, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ZGGS15 in solid tumor (advanced stage), sponsored by Zelgen. Primary endpoints: Dose-Limiting Toxicities at 21 days, Maximum Tolerated Dose at 24 months and 1 more. Started Jul 2023; status: completed.
02
Drugs
ZGGS15
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05864573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05864573.